2018 Pilot & Feasibility FUNDING OPPORTUNITY
Expression of Intent due Wednesday, August 1, 2018
Full application due Tuesday, September 4, 2018 (see"Submitting an Application")
Amount of funding:
Applicants may request up to $50,000 in direct costs for one or two year duration of the administrative supplements under this program.
Most Pilot and Feasibility Projects will be a one-year project and continuation of a project beyond its first year will be contingent upon the success of the previous year.
Start date: January 1, 2019
Purpose and Request for Applications
The Diabetes Research Center (SDRC) is soliciting new Pilot and Feasibility Projects. The focus of the SDRC Pilot and Feasibility (P&F) Program is to provide seed funds to help develop new investigators as well as support innovative and/or high-risk proposals from more senior investigators involved in any aspect of diabetes related research, including but not limited to basic sciences, economics, population sciences, translational research and clinical research.
The approved P&F Project proposals will assist current and future applications to the NIH/NIDDK to support the SDRC and this P&F program. However, institutional funds may be used to supplement some of these projects.
- Stanford or VA investigators (with UTL, MCL, NTLR, CE faculty appts. or instructors) with M.D., M.D./Ph.D, or PhD. degrees. [CE faculty PI waivers are not required.]
- Each applicant must have at least two years of full-time laboratory/clinical research experience after receiving the advanced degree.
- Applications from established investigators new to diabetes research are also encouraged.
Preference will be given to:
1) younger investigators: Assistant Professors (with a UTL, MCL, NTLR or CE faculty appts, or instrutors) who have a high potential for extramural funding in the near future and to become independent investigators
2) applications that will utilize the clinical registry or biorepository developed by the Diabetes Clinical and Translational Core
3) applications that focus on translational studies of diabetes prevention and control; and
4) applications that involve a collaborative component between the laboratories of Stanford investigators.
Submitting an Application
Expression of Intent: Deadline August 1, 2018
A brief EOI is due by midnight, August 1st. This EOI can be transmitted by email. The EOI should include the PI’s name, list of participating investigators, a non-binding proposal title, and 2-4 sentence description of the proposal. This will be used to facilitate review of the proposals.
Application Deadline: Tuesday, September 4, 2018
Applicants should submit one electronic copy of the following as an e-mail attachment to Dr. Kraemer at email@example.com. Filenames of attachment should be in the format Lastname_DRC_P&F.pdf.
1. Title page with the following information:
- Stanford Diabetes Research Center
- Pilot and Feasibility Projects
- Project title
- project leaders and co-investigators' name, title, department and complete contact information
- Type of proposal: Basic vs Clinical vs Translational vs Prevention and Control (may be multiple)
- Topic: Diabetes/Obesity/endocrinology/Autoimmunity/Transplantation/Related complications (may be multiple)
2. 5 page description of proposed research, including the following:
- research plan with relevant illustrations
- description of research subjects involved (both human or animal)
- description of interdisciplinary characteristics of this project or if it utilizes Specialized Resources (SDRC has 4 diabetes specific research cores - Clinical and Translational Core, Immune Monitoring Core, Genomics and Analysis Core and Islet Research Core)
- explanation of how the proposed research fits into Diabetes related research
(note: references are not included in the 5 page limit)
Format: single-spaced, ½ inch margins, Arial or Helvetica font size 11 or larger
3. Detailed budget for up to $50,000 excluding F&A costs.
*Use PHS 398 budget form available for downloading from this NIH webpage:
4. Budget justification
5. Biosketches (NIH format) for the Project Leader and Co-Investigators
*NIH biosketch webpage: https://grants.nih.gov/grants/forms/biosketch.htm
6. Other Support (also NIH format). Please include both active and pending support.
*Sample "other support" form: https://grants.nih.gov/grants/funding/phs398/phs398.html
7. Agreement to provide progress reports and required presentations on P&F Project Progress to the SDRC.
The SDRC P&F Review Committee will review and recommend action on all Pilot and Feasibility Project applications.
Fredric B. Kraemer, M.D. receiving his Bachelor's degree in Chemistry from Emory University in 1970 and his M.D. from New York University in 1974. He was a house officer in Internal Medicine at Kings County/Downstate Medical Center (1974-1978) and a postdoctoral fellow in Endocrinology at Stanford University (1978-1982). He joined the faculty in the Department of Medicine at Stanford in 1983, with an appointment at the Palo Alto VA Hospital in 1988. Dr. Kraemer currently holds the Stanford University Professorship in Endocinology and is the Chief of the Divison of Endocrinology, Gerontology and Metabolism, as well as a staff physician at the VA Palo Alto Health Care System. He was Associate Chief of Staff for Research and Development at the VA Palo Alto Health Care System from 2002-2007. His clinical and research interests have been focused on diabetes and cellular lipid metabolism. Dr. Kraemer's research program has been supported throughout his career by grants from the NIH and the Department of Veterans Affairs. He has won several awards including a Special Emphasis Research Career Award from the NIH, a SmithKline Beecham Junior Faculty Award in Diabetes, and an Arteriosclerosis Special Recognition Award from the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. Dr. Kraemer has served as president of the Western States Affiliate of the American Hearth Association, on the Scientific Advisory Committee of the University of California Tobacco-Related Disease Program, and the University of Minnesota Obesity Center, and the Advisory Board of the Deuel Conference on Lipids. In addition, he has served on a number of grant review boards for VA, NIH, American Diabetes Association and American Heart Association.